Prelude Therapeutics (PRLD) Accumulated Expenses (2019 - 2026)

Prelude Therapeutics has reported Accumulated Expenses for 8 years, with the latest figure at $5.9 million in Q1 2026.

• Quarterly Accumulated Expenses fell 47.47% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (down 47.47% YoY) and the FY2025 annual result came in at $12.5 million, up 38.92% from the prior year.
• Accumulated Expenses slipped to $5.9 million in Q1 2026 per PRLD's latest filing, from $12.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $15.8 million in Q4 2023 and troughed at $3.0 million in Q1 2022.
• A 5-year average of $8.5 million and a median of $7.6 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses soared 269.92% in 2023, then tumbled 67.47% in 2024.
• Over 5 years, Accumulated Expenses stood at $13.1 million in 2022, then increased by 20.43% to $15.8 million in 2023, then plunged by 42.78% to $9.0 million in 2024, then jumped by 38.92% to $12.5 million in 2025, then slumped by 52.62% to $5.9 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.9 million, $12.5 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.